Acromegaly Treatment Market: Growth & Demand

The global acromegaly treatment market size is expected to reach USD 2.10 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 7.5% over the forecast period. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth.

Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019.

The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval.

For more info visit here: https://www.grandviewresearch.com/industry-analysis/acromegaly-treatment-market

Further key findings from the report suggest:

• Somatostatin analogs segment is expected to emerge as the largest product segment in terms of revenue share in the forthcoming years, owing to easy availability and cost-effective treatment procedure of the product
• Hospital and clinics end use segment accounted for the largest market share as all the surgical procedures are performed in these facilities. Easy availability of surgeons Is anticipated to further drive the segment
• North America held the dominant market share in 2018, due to favorable government insurance policies and increased investment in R&D by the pharmaceutical companies. For instance, In May 2018, U.S. Congress approved the Right to Try bill, wherein patients can try unproven medical therapeutics in case of serious illness including orphan diseases like acromegaly
• Asia Pacific acromegaly treatment market is anticipated to witness lucrative growth in near future due to rising healthcare expenditure and R&D initiatives by pharmaceutical companies
• Some of the key players are Novartis AG; Ipsen Pharma; Pfizer Inc.; and Chiasma Inc.

Request a Sample Copy@ https://www.grandviewresearch.com/industry-analysis/acromegaly-treatment-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Artificial Tendons & Ligaments: Growth & Trends

The global artificial tendons and ligaments market size is anticipated to reach USD 39.7 million by 2025 at an 11.3% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Adoption of artificial grafts is on a rise owing to several benefits over autologous and allogenic grafts, such as high tensile strength, no immune reaction, and abrasion resistance. Increase in number of sports injuries, coupled with rising government efforts to create awareness about sports injuries and available medical reimbursements, is anticipated to fuel market growth.

For instance, the Government of Finland in collaboration with UKK Institute has been conducting a ‘LiVE-program’ since 2016 to improve safety in sports increase awareness about injury risks, sports training, and content of physical activity sessions. Over the past several decades, increase in participation of children and adolescents has been observed in various sports such as football, soccer, bicycles, handball, basketball, and volleyball. Moreover, increase in awareness about physical fitness among people will contribute to market growth.

Other factors likely to contribute to market growth include rising preference for minimally invasive surgery, continuous advancements in surgical procedures, and growing funding and research activities to develop novel materials for synthetic tendons and ligaments. Moreover, positive outcomes reported through various clinical trials pertinent to usage of artificial ligaments will accelerate growth in the near future. For instance, according to a study published in 2017 in NCBI, patients treated with artificial ligament after femoral tumor resection and reconstruction procedures exhibited a more stable hip joint and more active range of movement as compared to patients who did not received a synthetic ligament.

For more info visit here: https://www.grandviewresearch.com/industry-analysis/artificial-tendons-ligaments-market

Artificial Tendons & Ligaments Market Report Highlights

• The knee injuries segment held a major share in 2018 owing to increase in incidences of knee injuries, coupled with faster recovery observed with the use of artificial ligaments in comparison to autologous or allogenic grafts
• The hospitals and clinics end-use segment is expected to hold a significant share during the forecast period. Growth of the segment can be attributed to higher readmission rate for treatment of ACL reconstruction procedures and collaborative activities between key players and orthopedic clinics to create awareness about artificial tendons and ligaments.
• As of 2018, Europe accounted for the largest market share. Surge in number of sports injuries among young athletes, rising geriatric population prone to orthopedic disorders, and presence of key players in the region will boost the regional market
• The U.K. artificial tendons and ligaments market is expected to grow substantially over the forecast period. This growth is predicted to be majorly driven by increasing adoption of artificial tendons and ligaments, rising incidence of accidents, R&D of innovative product design, and favorable patient demographics.
• Growing healthcare expenditure, coupled with rising penetration of health insurance in Latin America and Asia Pacific countries such as China, India, Brazil, and Argentina are providing considerable growth opportunities to market players
• Industry players have been involved R&D activities to deliver novel products in the market. Companies are also strategically involved in expanding their geographical presence through distribution agreements to expand their customer base.

Request a Sample Copy@ https://www.grandviewresearch.com/industry-analysis/artificial-tendons-ligaments-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Virus Filtration Market Size Worth $7.0 Billion By 2026

The global virus filtration market size is expected to reach USD 7.0 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 12.7% during the forecast period. Increasing demand for biological products such as vaccines, therapeutic proteins, blood and blood products, cellular and gene therapy, tissue, and stem cell products is a major factor driving the growth. Biopharmaceuticals are mainly derived from human, animal, and plants and therefore require a scrutinized virus filtration procedure to avoid virus contamination in the production. Therefore, the necessity of this procedure during the production of biologics is expected to boost the market growth.

Many leading biopharmaceuticals and biotechnology manufacturers are involved in R&D to develop innovative biological products. For instance, in 2016, Pfizer Inc. invested USD 7,872.0 million in R&D, which was around 8% more than the R&D investment in 2015. This investment was mainly made to boost innovation and productivity in R&D to accomplish a sustainable pipeline of vaccines and differentiated therapies with lucrative commercial opportunities. Virus filtration is an important step in biologics development, thus, increasing R&D on biologics is expected to drive the product demand.

For more info visit here: https://www.grandviewresearch.com/industry-analysis/virus-filtration-market

Further key findings from the report suggest:

• Consumables was the largest revenue generating segment in 2018 owing to the increased usage of consumables including reagents, kits, and membranes in biologics downstream processing
• Chromatography technology segment is projected to expand at the fastest CAGR during the forecast period, owing to advancements such as disposable or single-use membranes that eliminate the risk of a potential virus contaminant
• Biologicals segment held the largest market share in 2018 and is projected to maintain its dominance during the forecast period due to rising prevalence of chronic diseases such as cancer, blood disorders, and diabetes
• The biotechnology and biopharmaceutical companies segment is projected to expand at the fastest CAGR over the forecast period owing to increasing investment in R&D and production of biologics
• North America led the virus filtration market in 2018 primarily due to the presence of several leading biotechnology companies and increased R&D activities
• Asia Pacific is estimated to expand at the highest CAGR during the forecast period. Growing presence of CROs in countries including China and India due to the presence of a large genome pool, less stringent regulations, and availability of economical labor force is contributing to the regional growth
• Some of the major players are Merck KGaA; Sartorius; Danaher; Thermo Fisher Scientific, Inc.; Charles River Laboratories International, Inc.; GE Healthcare; Asahi Kasei Medical Co., Ltd.; WuXi PharmaTech (Cayman) Inc.; Lonza; and Clean Cells

Request a Sample Copy @ https://www.grandviewresearch.com/industry-analysis/virus-filtration-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Preimplantation Genetic Testing Market Worth $107.3 Million By 2024

The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.

High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.

For more info visit here: https://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market

Further key findings from the report suggest:

• Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018
• Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in near future
• Advancements in detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018
• Expanding utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is expected to fuel the growth of X-linked diseases segment
• Implementation of PGT in embryo HLA typing for stem cell therapy is expected to impose segment growth. This is further attributed to the advantages pertaining to PGS testing for identification of HLA compatible embryos during stem cell therapy
• Europe accounts for largest revenue share in 2018 owing to increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures
• Asia Pacific market is observed to reveal the fastest CAGR due to the rise in medical tourism and the continuous development of IVF and PGD clinics in Asian countries
• Key players that have commercialized PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others
• Key participants are actively involved in expansion of the distribution network for their products as well as R&D activities for the development of novel PGT services. In October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.

Request a Sample Copy @ https://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Auto-injectors Market Size Worth $3.2 Billion by 2026

The global auto-injectors market size is expected to reach USD 3.18 billion by 2026, according to a new report by Grand View Research, Inc, exhibiting a CAGR of 19.5%. Rising incidence of anaphylactic shock and other diseases such as diabetes, rheumatoid, & multiple sclerosis along with increasing approvals of auto-injectors are impelling growth.

Increasing prevalence of life-threatening allergies and rising demand for these devices are expected to aid growth. As per the Food Allergy Research & Education, around 200, 000 people every year need emergency medical care for allergic food reactions.

In addition, increasing approvals are anticipated to drive growth. For instance, in August 2018, U.S. FDA approved the first generic epinephrine auto-injector of Teva Pharmaceuticals to treat emergency allergic reactions, including anaphylaxis. Generic versions of EpiPen Jr & EpiPen of 0.15 mg & 0.3 mg, respectively, are indicated for pediatric and adult patients weighing more than 33 pounds.

Moreover, manufacturers are also developing new products and innovative technologies, which is expected to propel market growth. For instance, in June 2018, AbbVie GK launched Humira, which is a fully human antitumor necrosis factor alpha monoclonal antibody formulation with lock function & injection start & end alerts as well as an inspection window and injects completely in 10 seconds. Demand for these devices is increasing as they are designed in accordance with patient acceptance and compliance. Technological advancements are anticipated to make them more convenient and user-friendly. This is encouraging patients to adopt this technology for chronic illnesses.

For more info visit here: https://www.grandviewresearch.com/industry-analysis/auto-injectors-market

Auto-injectors Market Report Highlights

• Disposable auto-injectors emerged as the largest segment owing to convenience and ease of use
• Homecare settings accounted for largest share in end-use segment owing to increasing demand of products for daily administration of insulin
• North America dominated the auto-injectors market with largest share in 2018. Increasing demand for new technologies along with advanced healthcare infrastructure is expected to boost market growth during the forecast period
• Asia Pacific is expected to witness fastest growth during the forecast period owing to increasing number of diabetic patients
• Some of the key players are Eli Lilly; Scandinavian Health Ltd.; AbbVie, Inc.; Amgen; Owen Mumford; Ypsomed; Teva Pharmaceutical; Biogen Idec; Mylan N.V.; Pfizer, Inc.; and Sanofi

Request a Sample Copy @ https://www.grandviewresearch.com/industry-analysis/auto-injectors-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Orthopedic Biomaterials Market Growth & Trends

The global orthopedic biomaterials market size is expected to reach USD 23.5 billion by 2025 registering a CAGR of 10.3%, according to a new report by Grand View Research, Inc. Increasing incidence of degenerative joint disease and musculoskeletal disorders is the key factor driving the market. In addition, increasing geriatric population susceptible to orthopedic conditions arising due to low bone density and advancing bone related disorders is expected to boost the product demand over the forecast period.

Ceramics & bioactive glass was the dominant material type segment in 2018 on account of growing demand for these materials due to their high compression strength. In addition, ceramics & bioactive glass biomaterials are preferred over their counterparts as they have a high affinity to integrate with the surface material of the bone. However, polymer biomaterial segment is expected to witness the fastest CAGR from 2019 to 2025 owing to high usage of these materials for the reconstruction and fixation procedures of the spine, hip, and knee.

Orthopedic implants led the application segment in 2018 and are expected to remain dominant over the forecast period. Increasing number of trauma cases is one of the major factors driving the growth of this segment. Orthobiologics segment is anticipated to witness the fastest CAGR of 10.8% from 2019 to 2025. Increasing adoption of biomaterials in various orthobiologics for the treatment of spinal and other reconstructive surgeries is anticipated to drive the growth of this segment.

Led by U.S. North America led the market in 2018 owing to high demand for joint replacement/reconstruction, bone repair, and, other orthopedic procedures due to the presence of target population. Moreover, rise in the demand for advanced treatment options coupled with increasing awareness about bio-resorbable products is expected to drive the product demand in future.

Full Research Report On Orthopedic Biomaterials Market Visit Here: https://www.grandviewresearch.com/industry-analysis/orthopedic-biomaterials-market

Orthopedic Biomaterials Market Report Highlights

• North America accounted for the largest revenue share in 2018 owing to large patient pool and high awareness regarding the use of bio-resorbable biomaterials
• Ceramics and bioactive glass segment led the market in 2018 owing to increased usage of these biomaterials for the restoration of damaged tissue and fixation surgeries and joint replacement surgeries
• Orthopedic implants was the dominant application segment in 2018 due to an increased number of trauma cases worldwide
• Some of the key companies in orthopedic biomaterials market are DSM Biomedical; Evonik Industries AG; Stryker Corp.; DePuy Synthes, Inc.; Zimmer Biomet; Invibio Ltd.; Globus Medical; Exactech, Inc.; Matexcel; AdvanSource Biomaterials Corp.; CAM Bioceramics B.V.; and Heraeus Holding

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/orthopedic-biomaterials-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Guidewires Market Size, Share, Future Growth Insights By 2025

The global guidewires market size is expected to reach USD 2.90 billion by 2025, at a CAGR 6.3% over a forecast period, according to a new report by Grand View Research, Inc. High prevalence of target diseases such as ischemic heart disease, brain aneurysm, and nephrolithiasis coupled with rise in preference for minimally invasive surgical procedures is anticipated to drive the growth. Increase in application of guidewires in neurovascular interventions is also among key factors driving the market.

Coronary heart disease is a major cause of disabilities and mortality globally. As per the Heart Disease and Stroke Statistics 2018, overall prevalence of myocardial infarction is nearly 7.9 million in U.S., which is 3% of the U.S. adult population, as of 2017. This study also states that the medical cost of coronary heart disease in projected to increase by 100% between 2013 and 2030. Moreover, as per OECD report, HEALTH AT A GLANCE 2015, the use of angioplasty has increased among the OECD countries, in the past 20 years. This is driving the demand for guidewires.

Technological advancements in terms of accessibility, improved flexibility with minimal deformity, and excellent tip shape retention is expected to drive the market. Motion Hybrid Wire Guide is an example of the technological advancement in guidewires. In January 2017, Cook Medical announced the launch of a two in one guidewire, Motion Hybrid Wire Guide. This product exhibits the features of Teflon fixed core guidewire and nitinol access guidewire into a single device.

Full Research Report On Guidewires Market Visit Here: https://www.grandviewresearch.com/industry-analysis/guidewires-market

Further key findings from the report suggest:

• In 2018, coronary guidewires held the largest revenue share owing to high demand in cardiovascular interventions
• Neurovascular guidewires segment is expected to expand at a rapid CAGR of 10.2% over the forecast period owing to the technological advancements and rising incidences of neurovascular disorders
• In 2018, coated guidewires segment held the leading market share of 90.6% owing to high preference for coated guidewires in minimally invasive surgeries
• North America held the largest revenue share of 33.7% owing to high adoption of technologically advanced devices leading to improved treatment rates and rise in preference of minimally invasive surgeries
• Asia pacific is expected to witness the fastest CAGR of 8.4% over the forecast period owing to growing geriatric population and burden of chronic diseases coupled with improving treatment rates
• Key players operating in the guidewires market include Boston Scientific Corporation, Abbott, Cordis (Cardinal Health) Angiodynamics, Medtronic, Stryker, Cook, Codman Neuro, and Terumo Medical Corporation.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/guidewires-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

Heparin Market Driven By Rising Prevalence Cardiovascular Disorders

The global heparin market size is expected to reach USD 7.4 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 1.6% during the forecast period. Rising prevalence cardiovascular disorders, deep vein thrombosis, and renal diseases among other chronic diseases is expected to boost the growth.

According to the data published in the American Heart Association, in 2018, approximately 92.1 million American adults were living with some form of cardiovascular diseases. Coronary heart disease is one of the leading cause of deaths in U.S. Furthermore, it was estimated that more than 23.6 million deaths will be observed by 2030 due to cardiovascular diseases.

Increasing demand for transfusion of blood, blood components, and plasma derivatives during surgical procedures, treatment of infectious diseases, and increasing survival rate are high impact rendering drivers for growth of the heparin market during the forecast period. Increasing demand for RBCs and platelets by various hospital divisions and clinics is expected to have a positive impact on the growth.

Growing geriatric population is anticipated to propel the market growth. According to an article published in 2018 in the United States Census Bureau, it is estimated that by 2035, population aged 65 years and above is expected to reach 78 million whereas children under the age of 18 may reach around 76.7million.

Rising incidence of immunological diseases, thrombosis, and hemostasis is likely to result in high demand for therapeutic plasma proteins. Manufacturing of plasma proteins led to an increase in the demand for purified plasma, further expected to fuel the market over the forecast period.

Full Research Report On Heparin Market Visit Here: https://www.grandviewresearch.com/industry-analysis/heparin-market

Heparin Market Report Highlights

• Low molecular weight heparin led the type segment in 2018 owing to its more predictable anticoagulant effect
• In 2018, ultra-low molecular weight heparin was estimated to be the fastest growing segment, owing to commercialization of enhanced version of products with improved pharmacological effects
• Subcutaneous route of administration led the market in 2018 and is estimated to be the fastest growing segment over the forecast period due to ease of administration
• Coronary artery disease was considered to be the largest application segment in 2018 and venous thromboembolism is projected to be the fastest growing segment in near future
• In 2018, outpatient led the end use segment and was estimated to register the fastest growth in the forthcoming years
• North America held the largest market share in 2018 owing to increasing prevalence of cardiovascular disorders and sports injuries. Asia Pacific is estimated to be the fastest growing segment over the forecast period
• Some of the key companies operating in the heparin market are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/heparin-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

ECG Equipment & Management Systems Market Worth $8.9 Billion By 2027

The global ECG equipment and management systems market size is expected to reach USD 8.9 billion by 2027, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.1% from 2020 to 2027. The growing prevalence of cardiac arrhythmia and technological advancements is expected to boost market growth during the forecast period.

Recent technologies in the market include ECG chip, which can be inserted in the body to record heart rhythms for a long duration; ECG data management solutions; and telemetry. Initiatives such as the Door-to-Balloon (D2B) time by the American College of Cardiology and “Mission: Lifeline” by AHA are expected to drive demand for wireless solutions and 12-lead ECG devices. Different technologies are being launched by players, either through innovation or partnerships. Some of these devices are HeartCheck ECG pen by CardioComm, online interface by emsCharts, and ZioPatch by iRhythm Technologies. For instance, in March 2020, Glanum Diagnostics developed a Holter ECG patch for the detection of arrhythmia, which records a patient’s heart data and timely transfers it to the virtual diagnostic center. The company’s plan is supported by EU funding under the HeartService project and CE certification is awaited.

The key players are engaging in new product launches to strengthen market presence. For instance, in July 2020, Philips launched Tempus ALS, a remote monitor, and a defibrillator solution for Emergency Medical Responders (EMS) in the U.S.

Full Research Report On ECG Equipment And Management Systems Market Visit Here: https://www.grandviewresearch.com/industry-analysis/ecg-management-systems-market

ECG Equipment And Management Systems Market Report Highlights

• Resting ECG system dominated the type segment in 2019. The market growth is characterized by improved clinical accuracy due to new product launches, advanced data analysis tools, and several technological advancements for better care and accurate diagnosis
• North America held the largest revenue share in the market in 2019. This is owing to the rising incidence of Atrial Fibrillation (AFib) in the region, aging population, technological advancements, shifting patient preference toward ambulatory ECG monitoring, the launch of next-generation wireless ECG monitoring devices, and technological collaborations between manufacturers
• In Asia Pacific, the market is expected to grow fast during the forecast period. The growth can be attributed to the rapidly growing geriatric population coupled with an increasing incidence of CVDs, rising disposable income, and developing healthcare infrastructure
• The industry is also witnessing dynamic mergers, acquisitions, and partnership & collaboration agreements. For instance in April 2019, In July 2020, BioTelemetry, Inc. acquired On. Demand remote patient monitoring and coaching system from one of the subsidiaries of Centene Subsidiary—Envolve People Care, Inc. The acquisition helped the company broaden its portfolio of acute care connected health products and services

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/ecg-management-systems-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Breast Cancer Drug Market Worth $38.4 Billion By 2025

The global breast cancer drug market size is expected to reach USD 38.4 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.7% during the forecast period. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends stoking market growth.

Global breast cancer drugs market is expected to grow lucratively as many players focus majorly on R&D of innovative treatments. They engage in extensive research to develop novel drugs for the treatment of the disease to gain a higher market share. There exists a growing pressure and need for novel therapies and treatment due to rapidly accelerating prevalence of diseases. The strong pipeline is expected to provide new and effective treatment options and improved outcomes than existing therapies.

With advancements in drug delivery systems, various target specific therapies have been customized and designed as a carrier to infuse the therapeutic agent to the target site. Carriers for inducing target therapy include modified anticancer agent’s specific to molecular-recognition-element, anticancer peptides, and nanoparticle-based anticancer drugs. For instance, HER2/neu protein is usually given in combination with other anti-cancer drugs in targeted therapy.

F. Hoffman-La Roche Ltd leads the breast cancer drugs market with Herceptin, Perjeta, and Kadcyla. However, rapid advancements in biosimilars with a goal to offer cost effective alternatives to patients is anticipated to put pressure on this space. For instance, in December 2017, the Food and Drug Administration (FDA) approved the first biosimilar of trastuzumab for HER2+ breast cancer.

Full Research Report On Breast Cancer Drugs Market Visit Here: https://www.grandviewresearch.com/industry-analysis/breast-cancer-drugs-market

Further key findings from the report suggest:

• HER2 inhibitors is expected to be the most preferred drug class segment over the forecast period, owing to their high specificity as they are subclass of target therapy
• CDK 4/6 inhibitor is expected to be the fastest growing segment over the forecast period. There are currently more than 45 CDK 4/6 inhibitor drug candidates in pipeline
• North America held the largest market share in 2017 owing to the factors such as the presence of key manufacturers in the country, high awareness and adoption, and well-established healthcare infrastructure among others
• Europe was estimated to be the second largest regional segment in 2017 due to increasing incidence of breast cancer and growing R&D investments
• Asia Pacific is anticipated to witness healthy growth over the next decade due to increasing incidence of breast cancer, rise in awareness about early diagnosis in emerging countries such as China and India.
• Companies such as F. Hoffmann-La Roche Ltd; Pfizer Inc.; AstraZeneca; Novartis AG; Astellas Pharma Inc.; and Eli Lilly and Company dominated the breast cancer drugs market
• The market is lucrative and competitive in nature as manufacturers engage in new product development to increase their product penetration. Moreover, they are entering into collaborations and partnerships to enhance their product portfolio.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/breast-cancer-drugs-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Trauma Devices Market Size Worth $11.2 Billion By 2025

The global trauma devices market size is expected to reach USD 11.2 billion in 2025, according to a new report by Grand View Research, Inc., registering a 6.1% CAGR during the forecast period. Increasing incidence of severe fractures and rising expenditure on research and development of trauma devices are among the key factors likely to drive the market during the forecast period. Medical devices used for fixation of small bones and joints are categorized under orthopedic trauma.

The market for trauma devices is likely to witness high growth in the coming years due to the rising geriatric population and surge in the number of road accidents. The market is driven by technological advancements, with key players introducing an array of products through extensive research capabilities and expanding their segment portfolio through partnerships with other players.

For instance, in July 2017, Cardinal Health acquired the patient recovery business from Medtronic for USD 6.1 billion. The acquisition helped expand Cardinal Health’s portfolio by adding 23 product categories, including segment leader brands such as Kendall, Curity, Kangaroo, Dover, and Argyle.

Full Research Report On Trauma Devices Market Visit Here: https://www.grandviewresearch.com/industry-analysis/trauma-devices-market

Further key findings from the report suggest:

• Rising number of road accidents and an increase in expenditure on research and development is expected to drive the trauma devices market from 2018 to 2025
• Osteoporotic fractures affect around 8.9 million people every year, mainly menopausal women, and causes osteoporotic fracture in more than 30.0% women over the age of 50
• Around 40.0% of trauma injuries occur due to falls and motor vehicle accidents. The elderly population as well as children below the age of 7 are more prone to falls. Motor vehicle accidents account for over 28% of trauma injuries
• Internal fixators dominated the market by type in 2017; however, external fixators are anticipated to grow at the fastest rate over the forecast period
• Key industry contributors include Depuy Synthes, Stryker; Zimmer Biomet, Smith & Nephew, Wright Medical Group N.V., Advanced Orthopaedic Solutions, Integra LifeSciences, Acumed, Bioretec Ltd., and Cardinal Health.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/trauma-devices-market/request/rs1

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com